LEAD-2 (Nauck) Sulf vs pbo 2009

NCT00318461

1 Treatments

Studied treatment  glimepiride (4 mg once daily).

Control treatment  placebo

Concomittant treatments  metformin

2 Patients

Patients  subjects previously treated with oral antidiabetes (OAD) therapy

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  double-blind

Design  -

Centers  -

Geographical area  -

Sizes  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All hypoglycemia</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HbA1c &lt;7height</td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
</tr>
</tbody>
</table>

5 References